Financing ·
Cardiol Therapeutics establishes $75M at-the-market equity offering program with Jefferies LLC
CRDLCardiol Therapeutics Inc.
Cardiol Therapeutics Inc. has entered into a sales agreement with Jefferies LLC to establish an at-the-market (ATM) equity offering program, allowing the company to sell up to US$75 million of its common shares from time to time through ordinary brokers' transactions on the Nasdaq Capital Market. The ATM Program is effective until the earliest of the sale of all offered shares, termination by either party, or the expiry of the Canadian Base Prospectus. Any net proceeds generated will be used at the company's discretion to support the development of CardiolRx for recurrent pericarditis, including potential New Drug Application support following Phase III MAVERIC trial outcomes, as well as the clinical development of CRD-38 and general corporate purposes. The Toronto Stock Exchange has conditionally approved the program, and Nasdaq has been notified. Cardiol Therapeutics Inc. is a late-stage life sciences company focused on advancing anti-inflammatory and anti-fibrotic therapies for heart disease.